Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of patients with chronic
myeloid leukemia (CML). However, continued use of these inhibitors has contributed to the …

When imatinib, the first tyrosine kinase inhibitor (TKI) developed for use in chronic
myelogenous leukemia (CML), was approved in 2001, the treatment of this disease was …

Simple Summary In this paper we perform an introduction about pregnancy-associated
cancer (PAC) and transplacental passage of antineoplastic agents. Furthermore, we …

The management of chronic myeloid leukemia (CML) diagnosed during pregnancy is a rare
and challenging situation. We report the treatment and outcome of 87 cases diagnosed in …

Since the introduction of tyrosine kinase inhibitors (TKIs) at the beginning of the millennium,
the outlook for patients with chronic myeloid leukemia (CML) has improved remarkably. As …

Tyrosine kinase inhibitors (TKIs) approved for chronic myeloid leukemia known to have
similar efficacies but different safety profiles. Therefore, the choice of patient-specific …

Simple Summary This review discusses the optimal selection of BCR-ABL1 tyrosine kinase
inhibitors (TKIs) as the first-line treatment for newly diagnosed chronic myelogenous …

Abstract Purpose of Review The goal of this review is to summarize what is known about
pregnancy in women with chronic myeloid leukemia (CML): there are very few guidelines …

The management of potentially life-threatening malignancies in pregnancy is complicated by
a lack of robust safety and efficacy evidence. This data shortage stems from a historical …

Background Given the increasing number and survival rates of reproductive-age patients
with chronic myeloid leukemia (CML), several studies aimed to elucidate optimum disease …